Home
Neurotargeting
News

Ebselen bonding decreases stability of 14-3-3 proteins

Ebselen, a promising drug candidate against cancer, bipolar disorder and the virus infection Covid-19, covalently bonds to cysteine residues in 14-3-3 adaptor proteins, triggering 14-3-3 destabilization and degradation in cells and intact brain tissue when used in therapeutic concentrations, potentially explaining the behavioral and anti-neoplastic effects of this drug.

molecyl
Photo:
MOLPHARM-AR-2020-000184

Main content